New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
August 10, 2018 - Alnylam announced the FDA approval of Onpattro (patisiran), for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
Download PDF
Return to publications
